DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/br3jj7/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update" report to their offering.
Together, AS and nr-axSpA are known as axial spondyloarthritis (axSpA). AS and nr-axSpA affect roughly 1.3 million and 700,000 individuals, respectively, in the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report and the prevalence is expected to grow mainly due to changes in diagnosis rates. The anti-TNFs have been effective in treating the signs and symptoms of axSpA, however, there is a lack of effective therapeutic classes, and no treatment options for patients who have failed anti-TNF therapy, representing a key unmet need and opportunities for drug developers.
Key Questions Answered
- What are the preferred anti-TNFs for and how will competition from pipeline agents and biosimilars affect sales? Are rheumatologists across the 7MM expected to prescribe biosimlars for axSpA?
- Will there be strong uptake of pipeline agents and how will Novartis's Cosentyx, J&J's Stelara, and Celgene's Otezla be used in the clinic?
- According to key opinion leaders (KOLs), what are the most important unmet needs in axSpA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
- How will disease awareness change over the forecast period and will this affect diagnosis?
- How is non-radiographic axial spondyloarthritis (nr-axSpA) treated and will the diagnosis and treatment change over the next decade? Which drugs are expected to gain label expansions into nr-axSpA?
Key Findings
- Increased diagnosis and treatment are key drivers in the axSpA market.
- Novartis's Cosentyx and J&J's Stelara will address the unmet need for drugs with novel MOAs and pose a threat to anti-TNFs, which are currently the only therapeutic class beyond NSAIDs.
- Label expansions into AS and nr-axSpA are expected to be an increasingly popular life-cycle management strategy for pharmaceutical companies developing drugs that target the immune system.
- Biosimilars are expected to change the landscape for axSpA and will create pricing pressure in the market.
Companies Mentioned
- AbbVie
- Pfizer
- Amgen
- Johnson & Johnson
- Merck
- UCB
- Novartis
- Celgene
- Takeda
- Mitsubishi Tanabe
For more information visit http://www.researchandmarkets.com/research/br3jj7/opportunityanalyze
